子宫内膜癌:从临床现实到分子治疗
Léa-Isabelle Renaud1, Elisabeth St-Laurent1, Coralie Compare2
1Département de Biologie Médicale, Laboratoire de Gynéco-Oncologie Moléculaire, Université du Québec à Trois-Rivières, Trois-Rivières, Canada.
Discover oncology
|October 14, 2025
概括
子宫内膜癌 (EC) 发病率正在上升,但存活率并没有显著改善. 本综述综合了临床和研究成果,以指导EC预防,诊断和治疗的未来进展.
科学领域:
- 妇科瘤学 妇科瘤学
- 翻译癌症研究 翻译癌症研究
背景情况:
- 子宫内膜癌 (EC) 是一个主要的妇科恶性瘤,发病率越来越高.
- 目前EC的生存结果显示最近的改善有限,需要新的策略.
- 肥胖率的上升与肥胖,人口老龄化和生殖模式的改变有关.
研究的目的:
- 提供对子宫内膜癌的临床和基本方面进行全面的审查.
- 为欧洲共同体弥合生物学研究和临床实践之间的差距.
- 为未来的研究和临床努力提供信息,以改善EC患者的治疗结果.
主要方法:
- 对遗传倾向,风险因素,分类,检测和治疗的临床评估.
- 审查欧洲共同体的共同研究模型,包括细胞系和动物模型.
- 分析PI3K/AKT/mTOR信号通路作为EC的关键驱动器和治疗目标.
主要成果:
- 确定了影响EC生存率和生活质量的关键临床因素.
- 突出了PI3K/AKT/mTOR途径在EC进展中的作用.
- 综合了关于EC研究模型和治疗目标的当前知识.
结论:
- 对临床和研究方面的全面了解对于推进EC护理至关重要.
- 针对PI3K/AKT/mTOR途径为EC治疗提供了一个有前途的途径.
- 未来的努力应侧重于将研究见解纳入临床实践,以改善患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


